Kicking off our first UCSF Radiation Oncology & @ucsfimaging.bsky.social Radiology Joint Research Symposium! Theranostics, Physics, Radiobiology
October 30, 2026 at 3:55 PM
Kicking off our first UCSF Radiation Oncology & @ucsfimaging.bsky.social Radiology Joint Research Symposium! Theranostics, Physics, Radiobiology
Theranostics Market Size, Share, Type, Trends, Report 2035 www.marketresearchfuture.com/reports/ther...
Theranostics Market Size, Share, Type, Trends, Report 2035
Theranostics Market growth is projected to reach 31.21 USD billion, at a 11.77% CAGR by driving industry size, share, top company analysis, segments research, trends and forecast report 2025 to 2035.
www.marketresearchfuture.com
October 30, 2026 at 7:52 AM
Theranostics Market Size, Share, Type, Trends, Report 2035 www.marketresearchfuture.com/reports/ther...
#RADX Radiopharm Theranostics Reports Business Update
https://www.stocktitan.net/news/RADX/radiopharm-theranostics-reports-business-dc95jlcuaxa6.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/RADX/radiopharm-theranostics-reports-business-dc95jlcuaxa6.html?utm_source=stocktitan-bluesky&utm_medium=social
www.stocktitan.net
November 2, 2026 at 1:00 PM
#RADX Radiopharm Theranostics Reports Business Update
https://www.stocktitan.net/news/RADX/radiopharm-theranostics-reports-business-dc95jlcuaxa6.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/RADX/radiopharm-theranostics-reports-business-dc95jlcuaxa6.html?utm_source=stocktitan-bluesky&utm_medium=social
AIEgen Targets the STAT3‒SUCLG2 Axis to Regulate Metabolism for Colorectal Cancer Theranostics
DOI: https://doi.org/10.1002/agt2.70383
DOI: https://doi.org/10.1002/agt2.70383
October 29, 2026 at 5:31 AM
AIEgen Targets the STAT3‒SUCLG2 Axis to Regulate Metabolism for Colorectal Cancer Theranostics
DOI: https://doi.org/10.1002/agt2.70383
DOI: https://doi.org/10.1002/agt2.70383
Theranostics market: $3.60B in 2025 to $12.01B by 2035, a 12.8% CAGR. Radioligand therapy approvals lead growth, North America holds 45% share. www.strategicrevenueinsights.com/industry/th... #MarketResearch
November 2, 2026 at 3:30 AM
Theranostics market: $3.60B in 2025 to $12.01B by 2035, a 12.8% CAGR. Radioligand therapy approvals lead growth, North America holds 45% share. www.strategicrevenueinsights.com/industry/th... #MarketResearch
🚨 #REVIEW 🚨
Sofias et al. discuss recent advances in radiotheranostic strategies, advances in nanotheranostic and microtheranostic platforms, and image-guided therapeutic and surgical interventions in oncology.
📖 👇
Sofias et al. discuss recent advances in radiotheranostic strategies, advances in nanotheranostic and microtheranostic platforms, and image-guided therapeutic and surgical interventions in oncology.
📖 👇
Cancer theranostics - Nature Reviews Cancer
Theranostics integrates diagnostic imaging with targeted therapy to enhance cancer treatment. In this Review, Sofias et al. discuss recent advances in radiotheranostic strategies, advances in nanotheranostic and microtheranostic platforms, and image-guided therapeutic and surgical interventions in oncology.
dlvr.it
October 30, 2026 at 5:23 PM
🚨 #REVIEW 🚨
Sofias et al. discuss recent advances in radiotheranostic strategies, advances in nanotheranostic and microtheranostic platforms, and image-guided therapeutic and surgical interventions in oncology.
📖 👇
Sofias et al. discuss recent advances in radiotheranostic strategies, advances in nanotheranostic and microtheranostic platforms, and image-guided therapeutic and surgical interventions in oncology.
📖 👇
United Theranostics Welcomes Amber Woodward-Smith as CFO for National Growth Initiative#United_States#CFO#Bethesda#United_Theranostics#Amber_Woodward-Smith
United Theranostics Welcomes Amber Woodward-Smith as CFO for National Growth Initiative
Amber Woodward-Smith has been appointed as the new CFO of United Theranostics, aiming to enhance patient access to advanced cancer therapies across the nation.
third-news.com
October 29, 2026 at 5:24 PM
United Theranostics Welcomes Amber Woodward-Smith as CFO for National Growth Initiative#United_States#CFO#Bethesda#United_Theranostics#Amber_Woodward-Smith
RRIDs were included in this in Chemistry – A European Journal paper. We value the author's support of reproducibility. #reproducibility #OpenScience #BetterScience
A Sequentially Activated Nanoreactor With DNAzyme Cascade for Precise Breast Cancer Theranostics
Read the full paper: A Sequentially Activated Nanoreactor With DNAzyme Cascade for Precise Breast Cancer Theranostics
doi.org
October 30, 2026 at 7:07 AM
RRIDs were included in this in Chemistry – A European Journal paper. We value the author's support of reproducibility. #reproducibility #OpenScience #BetterScience
Radiographers’ Perceptions of Artificial Intelligence and Theranostics: Implications for Job Security and Professional Adaptation
Artificial Intelligence (AI) and theranostics are transforming radiographic…
📄 PDF: sjoranm.com/sjoranm/article/download/101/89
#SJORANM #Radiology #NuclearMedicine
Artificial Intelligence (AI) and theranostics are transforming radiographic…
📄 PDF: sjoranm.com/sjoranm/article/download/101/89
#SJORANM #Radiology #NuclearMedicine
Radiographers’ Perceptions of Artificial Intelligence and Theranostics: Implications for Job Security and Professional Adaptation
Swiss J. Radiol. Nucl. Med. · Vol. 27 No. 1 · 2026-01-30 · DOI doi.org/10.59667/sjoranm.v27i1.18 · Artificial Intelligence (AI) and theranostics are transforming radiographic practice by enhancing diagnostic precision and enabling personalized treatment. However, these innovations raise concerns…
sjoranm.com
October 29, 2026 at 12:34 AM
Radiographers’ Perceptions of Artificial Intelligence and Theranostics: Implications for Job Security and Professional Adaptation
Artificial Intelligence (AI) and theranostics are transforming radiographic…
📄 PDF: sjoranm.com/sjoranm/article/download/101/89
#SJORANM #Radiology #NuclearMedicine
Artificial Intelligence (AI) and theranostics are transforming radiographic…
📄 PDF: sjoranm.com/sjoranm/article/download/101/89
#SJORANM #Radiology #NuclearMedicine
📑 Dual-Imaging Nanoparticles for Cancer
👉 mdpi.com/3780596
Gelatin-coated Gd₂O₃ nanoparticles combined enzyme-responsive doxorubicin release with MRI and photoacoustic imaging, suppressing tumor growth in mice.
#Theranostics #Nanomaterials
👉 mdpi.com/3780596
Gelatin-coated Gd₂O₃ nanoparticles combined enzyme-responsive doxorubicin release with MRI and photoacoustic imaging, suppressing tumor growth in mice.
#Theranostics #Nanomaterials
November 2, 2026 at 4:52 AM
📑 Dual-Imaging Nanoparticles for Cancer
👉 mdpi.com/3780596
Gelatin-coated Gd₂O₃ nanoparticles combined enzyme-responsive doxorubicin release with MRI and photoacoustic imaging, suppressing tumor growth in mice.
#Theranostics #Nanomaterials
👉 mdpi.com/3780596
Gelatin-coated Gd₂O₃ nanoparticles combined enzyme-responsive doxorubicin release with MRI and photoacoustic imaging, suppressing tumor growth in mice.
#Theranostics #Nanomaterials
⚠️ $RDPTF Radiopharm Theranostics: Estimated funding runway of only 0.70 quarters, Q1 FY26 operating cash outflow A$10.687M, and cash of A$7.462M—going-concern style disclosures triggered [HIGH RISK]
October 30, 2026 at 2:30 PM
⚠️ $RDPTF Radiopharm Theranostics: Estimated funding runway of only 0.70 quarters, Q1 FY26 operating cash outflow A$10.687M, and cash of A$7.462M—going-concern style disclosures triggered [HIGH RISK]
$RDPTF 🏥
Radiopharm Theranostics reported positive Phase 1 imaging data for RAD301 supporting advancement toward Phase 2 development in pancreatic ductal adenocarcinoma.
Selected from hundreds of headlines
More market highlights:
https://rayvio.app/dashboard/?utm_source=lifatpt
Radiopharm Theranostics reported positive Phase 1 imaging data for RAD301 supporting advancement toward Phase 2 development in pancreatic ductal adenocarcinoma.
Selected from hundreds of headlines
More market highlights:
https://rayvio.app/dashboard/?utm_source=lifatpt
November 2, 2026 at 1:03 PM
$RDPTF 🏥
Radiopharm Theranostics reported positive Phase 1 imaging data for RAD301 supporting advancement toward Phase 2 development in pancreatic ductal adenocarcinoma.
Selected from hundreds of headlines
More market highlights:
https://rayvio.app/dashboard/?utm_source=lifatpt
Radiopharm Theranostics reported positive Phase 1 imaging data for RAD301 supporting advancement toward Phase 2 development in pancreatic ductal adenocarcinoma.
Selected from hundreds of headlines
More market highlights:
https://rayvio.app/dashboard/?utm_source=lifatpt
The authors included RRIDs in their in Theranostics paper! RRIDs improve reproducibility in scientific research. #OpenScience #STMpublishing #ReproducibleResearch
Neuronal mitochondrial disaggregase CLPB ameliorates Huntington's disease pathology in mice
Read the full paper: Neuronal mitochondrial disaggregase CLPB ameliorates Huntington's disease pathology in mice
doi.org
November 1, 2026 at 7:00 AM
The authors included RRIDs in their in Theranostics paper! RRIDs improve reproducibility in scientific research. #OpenScience #STMpublishing #ReproducibleResearch
RRIDs were included in this in Theranostics paper. We value the author's support of reproducibility. #OpenScience #RRID #STMpublishing
PINK1/Parkin promotes liver regeneration via Sigma-1 ubiquitination to inhibit ER-Mitochondrial calcium transfer
Read the full paper: PINK1/Parkin promotes liver regeneration via Sigma-1 ubiquitination to inhibit ER-Mitochondrial calcium transfer
doi.org
November 1, 2026 at 7:00 AM
RRIDs were included in this in Theranostics paper. We value the author's support of reproducibility. #OpenScience #RRID #STMpublishing
The authors included RRIDs in their in Theranostics paper! We value the author's support of reproducibility. #OpenScience #STMpublishing #accelerateopenscience
Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy
Read the full paper: Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy
doi.org
October 30, 2026 at 7:02 AM
The authors included RRIDs in their in Theranostics paper! We value the author's support of reproducibility. #OpenScience #STMpublishing #accelerateopenscience
The authors included RRIDs in their in Theranostics paper! RRIDs improve reproducibility in scientific research. #RRID #methodsmatter #OpenScience
Single-cell RNA sequence analysis reveals USP32 as a therapeutic target to mitigate PD-L1-driven colorectal tumorigenesis in vitro and in vivo
Read the full paper: Single-cell RNA sequence analysis reveals USP32 as a therapeutic target to mitigate PD-L1-driven colorectal tumorigenesis in vitro and in vivo
doi.org
November 1, 2026 at 7:00 AM
The authors included RRIDs in their in Theranostics paper! RRIDs improve reproducibility in scientific research. #RRID #methodsmatter #OpenScience
New hope for metastatic prostate cancer! FDA-expanded approval means eligible patients can receive Pluvicto® earlier.
Could this targeted therapy be right for you? Take ARA’s PSMA questionnaire: https://www.ausrad.com/psma-intake/
#ProstateCancer #Pluvicto #psma #theranostics
Could this targeted therapy be right for you? Take ARA’s PSMA questionnaire: https://www.ausrad.com/psma-intake/
#ProstateCancer #Pluvicto #psma #theranostics
October 27, 2026 at 10:04 PM
New hope for metastatic prostate cancer! FDA-expanded approval means eligible patients can receive Pluvicto® earlier.
Could this targeted therapy be right for you? Take ARA’s PSMA questionnaire: https://www.ausrad.com/psma-intake/
#ProstateCancer #Pluvicto #psma #theranostics
Could this targeted therapy be right for you? Take ARA’s PSMA questionnaire: https://www.ausrad.com/psma-intake/
#ProstateCancer #Pluvicto #psma #theranostics
Isomer Engineering of NIR-II Aggregation-Induced Emission for the Theranostics of MRSA-Induced Abscess
DOI: https://doi.org/10.1002/agt2.70376
DOI: https://doi.org/10.1002/agt2.70376
October 26, 2026 at 4:28 AM
Isomer Engineering of NIR-II Aggregation-Induced Emission for the Theranostics of MRSA-Induced Abscess
DOI: https://doi.org/10.1002/agt2.70376
DOI: https://doi.org/10.1002/agt2.70376
How AI, #Theranostics and More Empowered Patients Have Led to Significant Changes in #Radiology
www.diagnosticimaging.com/view/ai-ther...
#RadRes #HLTH2026
www.diagnosticimaging.com/view/ai-ther...
#RadRes #HLTH2026
October 19, 2026 at 6:00 PM
How AI, #Theranostics and More Empowered Patients Have Led to Significant Changes in #Radiology
www.diagnosticimaging.com/view/ai-ther...
#RadRes #HLTH2026
www.diagnosticimaging.com/view/ai-ther...
#RadRes #HLTH2026
1/ Deep learning models can predict brain tumor contrast enhancement using only non-contrast MRI, according to a multicohort study in The Lancet Medical Imaging & Theranostics.
https://yesilscience.com/ai-in-nephrology-october-2026/
https://yesilscience.com/ai-in-nephrology-october-2026/
October 20, 2026 at 6:01 AM
1/ Deep learning models can predict brain tumor contrast enhancement using only non-contrast MRI, according to a multicohort study in The Lancet Medical Imaging & Theranostics.
https://yesilscience.com/ai-in-nephrology-october-2026/
https://yesilscience.com/ai-in-nephrology-october-2026/
A "molecular shock absorber" for cancer theranostics.
Deuterium substitution boosted fluorescence +26%, ROS +14%, and blood stability +21%—all at once.
In mice: complete tumor elimination, and surgery that caught invisible remnants.
www.eurekalert.org/news-release...
#CancerResearch #Theranostics
Deuterium substitution boosted fluorescence +26%, ROS +14%, and blood stability +21%—all at once.
In mice: complete tumor elimination, and surgery that caught invisible remnants.
www.eurekalert.org/news-release...
#CancerResearch #Theranostics
October 19, 2026 at 9:45 AM
A "molecular shock absorber" for cancer theranostics.
Deuterium substitution boosted fluorescence +26%, ROS +14%, and blood stability +21%—all at once.
In mice: complete tumor elimination, and surgery that caught invisible remnants.
www.eurekalert.org/news-release...
#CancerResearch #Theranostics
Deuterium substitution boosted fluorescence +26%, ROS +14%, and blood stability +21%—all at once.
In mice: complete tumor elimination, and surgery that caught invisible remnants.
www.eurekalert.org/news-release...
#CancerResearch #Theranostics
(WO2026208730A1) discloses DLL3-targeted cyclic peptide radioligands for imaging (^68Ga) and therapy (^177Lu, ^225Ac). Kelun-Biotech extends its conjugate strategy beyond ADCs into preclinical theranostics; tumour-to-kidney/marrow dosimetry versus antibody-based radioligands remains key.
October 19, 2026 at 5:46 AM
(WO2026208730A1) discloses DLL3-targeted cyclic peptide radioligands for imaging (^68Ga) and therapy (^177Lu, ^225Ac). Kelun-Biotech extends its conjugate strategy beyond ADCs into preclinical theranostics; tumour-to-kidney/marrow dosimetry versus antibody-based radioligands remains key.